Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Addition Therapeutics has emerged from stealth with ...
The Barbara Ann Karmanos Cancer Institute in Detroit has become the first and only independent cancer center in the U.S. to ...
Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children ...
Betibeglogene autotemcel gene therapy led to transfusion independence in 89% of patients with severe transfusion-dependent β-thalassemia. The trial involved 18 patients with specific genotypes, ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
Collaboration Leverages Made Scientific's Industry Expertise and Workforce Development Initiative to Empower the Next Generation of Cell and Gene Therapy Professionals PRINCETON, N.J. and NEWARK, N.J.
Please provide your email address to receive an email when new articles are posted on . One specialist argued that, in the future, gene therapy technologies will be the favored option for wet AMD.
As we continue our series exploring genetic medicine, both in this story and in Destiny's Child No Longer: Rewriting Genetic Fate, gene therapy stands at a crossroads. On June 16, Sarepta Therapeutics ...
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have developed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results